Circulating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqManV R Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni-and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.
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Colorectal cancer (CRC) is the third most common cancer worldwide with 1.36 million new cases annually. 1 The worldwide incidence varies up to 10-fold, with almost 55% of the cases occurring in more developed regions. Every year 694,000 CRC patients die from metastasis as the major cause of death. Approximately 20% of diagnoses are made in the metastatic stage with a median survival time of less than 2 years. 2 The lack of effective treatment options for the late CRC stages necessitates to better understand the processes of distant metastasis formation and to identify efficient markers for the patients' prognosis.
Several steps during metastasis formation are associated with changes in microRNA (miRNA) expression levels. 3 Altered miRNA abundances have been reported not only in tissues but also for circulating miRNAs, representing the miRNA population in the cell-free component of body fluids such as plasma and serum. In the past years, circulating miRNAs have been investigated as potential candidates for biomarkers for various cancers. [4] [5] [6] [7] Besides the proven role of miRNAs in cancer development and progression, 8 their high stability, easy access through minimally invasive techniques and the potential of repeated sampling makes them almost ideal biomarker candidates. 9, 10 which included the miRNA-200 family that has important roles in the epithelial-to-mesenchymal transition (EMT) and the reverse mesenchymal-to-epithelial transition (MET). [12] [13] [14] [15] [16] . Recent studies have proposed the involvement of the miR-200 family in these processes in CRC tissues and cell lines. 17, 18 EMT and MET are discussed to be general processes in epithelial cancer progression although there is controversy of the requirement of EMT for invasion and metastasis. 19, 20 To date only a few studies are available investigating circulating miRNAs and prognosis of CRC. Regarding the miR-200 family members, serum miR-200c was reported to serve as a biomarker for prognosis and the prediction of metastasis. 21 A further study showed dynamic changes of serum miR-200c of CRC patients with different prognosis after surgery and chemotherapy. 22 For high plasma levels of miR-141, a significant association with poor survival in metastatic CRC patients was found in two independent sample cohorts. 23 However, the most limiting factor in many studies on CRC is the rather small sample size, which requires verification in larger cohorts. Here, we aimed to evaluate the role of circulating miRNAs as potential prognostic markers for CRC with a specific focus on miRNAs known to be involved in tumor progression and metastasis formation processes.
Material and Methods

Study cohort
All included patients were recruited for an ongoing German population-based case-control study (DACHS: Darmkrebs: Chancen der Verh€ utung durch Screening), described in detail before. 24, 25 In brief, participating patients living in the RhineNeckar-Odenwald region had to be at least 30 years old when first diagnosed with invasive primary CRC. Extensive patient information was gained by standardized questionnaires, carried out by trained interviewers. For over 93% of the patients' blood samples had been collected. Blood sampling was done at various time-points: prior (within 2 weeks) to surgery and after surgery, including before, during and after adjuvant therapy. Follow-up information concerning vital status, date and cause of death was obtained by the local population registries and health authorities after 3 and 5 years. The study was approved by the ethical committees of the Medical Faculty of the University of Heidelberg and of the Medical Chambers of Baden-W€ urttemberg and Rhineland-Palatinate. Written informed consent was obtained from each participant. Figure 1 gives an overview of the patients we analyzed here. We included patients with all tumor stages and different adjuvant therapies (chemotherapy and radiotherapy), diagnosed and treated between 2003 and 2007. Post-surgical blood samples from 315 randomly chosen non-metastatic patients and all recruited metastatic patients (n 5 262) were selected for the isolation of circulating miRNAs from plasma. After the exclusion of patients with neoadjuvant treatment and samples with too little starting volume of plasma, the study cohort finally consisted of 309 non-metastatic (stage I, II and III) and 234 metastatic (stage IV) CRC patients. All clinicopathological data, obtained from medical records are summarized in Table 1 . For the initial miRNA profiling step, a sub-cohort of 20 non-metastatic and 20 metastatic colon carcinoma (CC) patients was determined. For this profiling cohort we used only patients classified with 'good' or 'bad' prognosis, respectively (depicted in Fig. 1 ). The 'good' prognosis subgroup was defined as no event (relapse, metastasis or cancer-related death), occurring for >5 years in non-metastatic and 2.5 years in metastatic cases and 'bad' prognosis as an event occurring within one year after diagnosis. The 'good' and 'bad' prognosis patients within the non-metastatic and the metastatic group of the profiling cohort were matched for sex, age and stage. Hemolytic samples as well as blood samples collected <10 days after surgery were excluded.
Blood sampling, processing and miRNA isolation from plasma EDTA blood samples were kept at 48C and processed within 24 hrs after collection. After centrifugation at 2100 g for 10 min, the plasma was stored at 2808C until use. Before isolation of circulating miRNAs, a high-speed centrifugation step at 15,500 g for 10 min at 108C was added to remove cell debris and fragments. Total RNA (including miRNAs) was extracted from 160 ml plasma using TRIzol LS (Sigma, Germany) for denaturation and phase separation in combination with miRNeasy Mini Kit (Qiagen, Germany) as described before. 10 Besides 10 mg of glycogen, 3.5 ml of a synthetic cel-miR-39 (1.6 x 10 8 copies/ml; Qiagen, Germany) was spiked-in. 1.5 volumes of absolute ethanol were added to the aqueous phase and the mixture was applied to miRNeasy Mini columns (Qiagen, Germany) and processed according to manufacturer's protocol. RNA was eluted in 30 ml of RNase-free water.
What's new?
Metastasis is the major cause of death for colorectal cancer (CRC) patients. Prognostic markers that are constantly measurable using liquid biopsies could facilitate the earlier prediction of relapse events and metastasis formation. In a prospective study cohort of 543 colorectal cancer patients, the authors evaluated the role of circulating miRNAs as potential prognostic markers for CRC with a specific focus on miRNAs known to be involved in tumor progression and metastasis formation. MiR-122 and several members of the miR-200 family were identified as prognostic markers, suggesting their potential use in the development of a multi-marker blood test for CRC prognosis.
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miRNA profiling with custom TaqManV R array MicroRNA cards
For the initial miRNA profiling, the levels of 95 miRNAs selected from literature were measured in the profiling cohort consisting of 40 CC patients from the study cohort that were classified as patients with 'good' or 'bad' prognosis (see Fig. 1 ). The 95 miRNAs selected for investigation included the miRNAs of the prognostic breast cancer panels discovered in our group before, 4,11 other miRNAs known to be involved in the EMT/MET processes as well as miRNAs with previously described prognostic potential in CRC and other gastrointestinal cancers. All included miRNAs are listed in Supporting Information Table 1 . The miRNA profiling using Custom TaqManV R Array MicroRNA Cards (Applied Biosystems, USA) was conducted according to the manufacturer's protocol. In brief, 3 ml of miRNA eluate were reversely transcribed using the TaqMan MicroRNA Reverse Transcription Kit and the Custom RT Primer Pool. The cDNA was preamplified for 14 cycles with the TaqMan PreAmp Master Mix and the Custom PreAmp Primer Pool. The diluted (1:5), preamplified product of four samples was loaded on an array card (96a format). An Applied Biosystems 7900HT thermocycler was used for real-time PCR under the following conditions: 508C for 2 min, 94.58C for 10 min, followed by 40 cycles of 978C for 30 sec and 59.78C for 1 min. Cycle threshold (Ct) values (number of cycles required for the fluorescence signal to cross the baseline) were determined using the software ExpressionSuite v1.0.3 (Applied Biosystems, USA) with automatic baseline settings and a manually set threshold of Ct 5 0.2. Ct 5 35 was chosen as detection limit. All miRNAs with <50% Ct values below 35 were excluded from further analyses. In all other cases, Ct values above 35 and those classified as 'undetermined' were considered as 'below detection limit' and were set to Ct 5 35.
Validation of selected marker candidates
Besides the significantly deregulated miRNAs identified by the Custom TaqManV R Array MicroRNA Cards, all miR-200-family members were selected for validation in the whole study cohort. Two additional miRNAs (miR-23a and miR451a) were investigated as control of the hemolytic state of the plasma samples, as described before 26 . We used Ct (miR-23a) -Ct (miR-451a) > 7 as an indicator for hemolytic plasma. Reverse transcription (RT) reactions were performed in three miRNA pools using the TaqMan MicroRNA Reverse 
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Transcription Kit (Applied Biosystems, USA) and miRNA specific RT primers (Applied Biosystems, USA) for each selected miRNA (see Supporting Information Table 2 ). Each RT reaction comprised 0.5 ml of each miRNA-specific RT primer (5x), 0.15 ml dNTPs (100 mM), 0.19 ml Rnase Inhibitor, 1.5 ml 10x RT buffer, 1 ml/1.5 ml/2 ml Multiscribe Reverse Transcriptase (depending on the used miRNA-pool), 2 ml miRNA template and water up to the total volume of 15 ml. The GeneAmpV R PCR System 9700 (Applied Biosystems, USA) was used to carry out the RT reactions under following conditions: 168C for 30 min, 428C for 30 min and 858C for 5 min, followed by a hold at 48C. For RT pool (3) a preamplification step (10 cycles, final reaction volume of 10 ml) after RT was necessary using TaqManV R PreAmp PCR Master Mix (2x) (Applied Biosystems, USA) following the manufacturer's instructions. Prior to qPCR, the RT products of RT pool (1) and pool (2) were diluted with water to a final volume of 50 ml and 40 ml and the preamplified product of RT pool (3) to a final volume of 50 ml. TaqMan real-time PCR reactions were run in triplicates using a LightCycler 480 thermocycler (Roche, Germany) as described earlier. 27 
Statistical analyses
Statistical analyses were performed using the computational environment R version 3.1.3 (http://www.r-project.org/) and SPSS version 17.0. Raw miRNA data (profiling and validation data) was normalized to spiked-in cel-miR-39 as described by Kroh et al. 28 The miRNA expression levels were defined as 2 -Ct . For the selection of candidates from the profiling step multivariate survival analyses were carried out with Cox proportional hazards models. The covariates age, sex and for non-metastatic CRC cases additionally the stage (I, II and III) were included. MannWhitney-test (univariate analysis) was used to investigate the differences in miRNA levels between non-metastatic and metastatic CC patients. MiRNAs with p < 0.1 for non-metastatic and p < 0.05 for metastatic cases were the only criteria to select potentially relevant candidates for validation.
In the validation study, non-parametric tests (Mann-Whitney, Spearman's rank correlation and Jonckheere-Terpstra) were used for the analyses of associations between miRNA levels and clinicopathological factors. The effects of hemolysis and the time-point of blood sampling on the miRNA levels were considered in linear regression models. The effect of the hemolytic sample status on patients' survival was studied with Cox proportional hazards models. In addition, logistic regression models were used to test hemolytic sample status with respect to dichotomized patients' prognosis. For analysis of the endpoint 'prognosis' in the whole study cohort the same criteria as for the prognosis classification in the profiling step were used. Patients not fitting the criteria for the 'good' or 'bad' prognosis group (for definitions see Fig. 1 ) were included in the 'intermediate' prognosis group. Only CRC plasma samples from blood samples drawn within two months after surgery were included in logistic regression models.
All further analyses in the validation cohort regarding time to event endpoints (OS and RFS) were conducted using Cox proportional hazards models treating delayed entries as left-truncated data. 29 For multivariate analyses the covariates age, sex, CRC location (colon vs. rectum) and the stage (I, II and III) were considered. All given odds ratios (OR) and hazard ratios (HR) are based on change from the lower to upper quartile of the miRNA Ct value distribution. KaplanMeier curves were generated for the two subgroups 'low' and 'high' miRNA expression using the median Ct value of the respective miRNAs as cut-off. The sample cohort was divided into non-metastatic CRC samples (stage I, II and III) and metastatic CRC samples (stage IV) for all analyses. In all analyses of the validation study, a two-tailed significance level of 0.05 was used (without correction for multiple testing).
Results
miRNA profiling with custom TaqManV R array MicroRNA cards
In an initial profiling step 95 miRNAs were analyzed in blood plasma samples of 20 non-metastatic and 20 metastatic colon cancer patients with 'good' or 'bad' prognosis, respectively. After data pre-processing 83 miRNAs were suited for analysis. Multivariate survival analyses revealed that miR-365a (p 5 0.049) displayed prognostic potential for metastatic colon cancer as did [21] [22] [23] although the profiling data did not indicate these miRNAs as candidates.
Correlation of plasma miRNA levels to clinicopathological factors
The correlations between the miRNA levels and clinicopathological characteristics of the validation cohort are shown in Supporting Information Table 3 . In non-metastatic CRC patients the amounts of miR-200b, miR-200c, miR-203a and miR-365a were weakly correlated to the patients' age. Levels of miR-181b were slightly increased in female non-metastatic CRC patients compared to male patients (p 5 0.030) while levels of miR-141 were weakly increased in non-metastatic colon cancer samples compared to rectum cancer samples Dependency of plasma miRNA levels on time-point of blood sampling and hemolysis
The time-point of blood sampling in relation to surgery was identified as a factor that strongly influenced the amounts of most circulating miRNAs analyzed in the validation cohort (Supporting Information Table 4 ). Six out of the eleven miRNAs displayed a significant dependency of the time-point of blood sampling in the non-metastatic CRC patients. In metastatic CRC patients, the dependencies were more significant and only for miR-122 there was no significant association. For survival analyses the time-point of blood sampling was considered as time of entry into the study using a delayed entry model. Almost 16% (87 out of 544) of the plasma samples were characterized as hemolytic. However, hemolysis influenced the levels of only a few investigated miRNAs (Supporting Information Table 4 ). Especially for miR-144 a strong influence was observed in both, in non-metastatic and metastatic CRC, which was reflected by much higher miRNA levels in hemolytic samples than in non-hemolytic samples. MiR-181b 
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was present in significantly higher amounts in hemolytic samples from metastatic CRC. Slightly reduced levels of miR-122 in non-metastatic CRC samples and miR-365a in metastatic samples were also observed. Interaction analysis between miRNA expression and hemolytic status with respect to patients' prognosis and survival revealed that only miR200a showed an interaction between hemolysis and the prognosis subtype as well as RFS within the metastatic CRC cases while in non-metastatic CRC patients only for miR-203a an interaction between expression level and hemolysis regarding RFS was observed. For OS miRNA expression did not interact with the hemolytic sample status. Since the observed interactions were only marginally significant, hemolytic status was not considered as a covariate for survival analyses.
Survival analyses
All results of the analyses concerning the patients' prognostic subtype are provided in Table 2 , the results for OS and RFS in Tables 3 and 4 OR, odds ratio; HR, hazard ratio; CI, confidence interval.
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Discussion
In this study, we initially profiled the blood plasma levels of 95 miRNAs in colon cancer patients. Eleven miRNAs were selected for validation in plasma samples of 543 CRC patients. Three of these miRNAs, miR-122, miR-200a and miR-200b, were identified as potential prognostic blood based biomarkers.
An advantage of this study is the study cohort representing a realistic clinical cohort. By its very nature, this is accompanied by a considerable heterogeneity of the cohort in the context of clinicopathological parameters since it included patients with all CRC stages and different therapies as well as further factors that may influence plasma miRNA levels which arise from the necessities and difficulties in day-to-day sample collection in a routine clinical setup.
As hemolysis was found to be an important source of variation in miRNA profiles 30, 31 we determined the levels of two miRNAs as control for the hemolytic state of the plasma samples, as described by Blondal et al. before. 26 MiR-451a is known to be enriched in erythrocytes and its levels in blood plasma are therefore strongly influenced by hemolysis 32 whereas miR-23a levels are reported to be stable in plasma and not affected be hemolysis. 26 By using Ct (miR-23a) -Ct (miR-451a) > 7 as an indicator for the high risk of hemolysis, 16% (87 out of 543) of the plasma samples were characterized as hemolytic. A few of the measured miRNAs were influenced by hemolysis, with a notable effect only for miR-144 in the whole study cohort. This is in line with a previous report stating that miR-144 is also enriched in erythrocytes, similar to miR-451. 33 In this study cohort blood samples were drawn at various time-points in respect to surgery. The levels of the measured miRNAs in the validation cohort were affected by the timepoint of blood sampling. Few studies have investigated the effect of different blood sampling time-points on circulating miRNA levels so far. 22, 31, 34, 35 Chen et al. 22 demonstrated that the circulating miRNA levels of miR-155, miR-200c and miR-210 change dynamically in CC patients after surgery and treatment and that alterations can be associated with disease progression and prognosis. They found levels of the miRNAs increased again before diagnosis of local relapse or distant metastasis whereas the miRNA levels remained at low levels in patients with good prognosis. We observed similar results for breast cancer before, 4, 11 and could show that an increase of miR-200a, miR-200b, miR-200c, miR-210, miR-215 and miR-486-5p in plasma samples of former breast cancer patients can indicate metastasis up to two years before clinical diagnosis. 11 These findings generally fit to the results of the survival analyses presented here. To correct for the time-point of blood sampling, we used a delayed-entry model when studying patients survival time, which sets the time of blood sampling as entry time. 29 Elevated levels of miR-122 were associated with the 'bad' prognosis subgroup in metastatic CRC. In addition, increased OR, odds ratio; HR, hazard ratio; CI, confidence interval.
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miR-122 expression was also related to shorter OS in nonmetastatic and metastatic CRC patients and also shorter RFS in non-metastatic and metastatic CRC patients. Several studies demonstrated the importance of miR-122 in hepatocellular carcinoma investigating human tissue, plasma and serum samples as well as cell lines. [36] [37] [38] [39] Mir-122 was also postulated as biomarker for viral-, alcohol-, and chemical-related hepatic diseases. 40 Liver is the most commonly diagnosed site of metastasis in CRC. 41 In our cohort almost 80% of the metastatic patients (184 out of 234) had been diagnosed with liver metastases. We investigated if the differences in plasma miR-122 abundances are mainly observed in metastatic patients with liver metastases and indeed patients with only other metastatic sites showed similar miR-122 levels as nonmetastatic CRC patients. Thus, miR-122 is a strong candidate marker for the occurrence of liver metastasis. These results are in concordance with another study that reported miR-122 to be the most abundant miRNA found in liver metastases in comparison to non-metastatic CRC tumor tissue. 42 We found elevated miR-122 levels not only in metastatic CRC samples but also in non-metastatic CRC patients resulting in shorter RFS and OS times. Thus, miR-122 plasma levels might be able to predict a subgroup with bad prognosis prior to a clinical manifestation of liver metastasis. This subgroup with poor prognosis could receive the necessary treatment sooner and benefit from a more intensive adjuvant therapy. Interestingly, He et al. reported that an overexpression of miR-122 re-sensitized 5-Fluorouracil-(5-FU) resistant colon cancer cells to 5-FU by inhibiting PKM2. 43 Therefore, it is possible that high levels of miR-122 might serve as a predictive marker to overcome 5-FU resistance which warrants investigation in dedicated studies. Of all validated miRNAs in this study, only miR-122 was independent from the time-point of blood sampling in metastatic CRC samples. This underlines the robustness of the proposed use of miR-122 as a biomarker.
Besides miR-122, all miR-200 family members (miR-141, miR-200a, miR-200b, miR-200c and miR-429) showed significant associations to patients' survival, the prognosis subgroups or correlations to clinical characteristics. The miR-200 family possesses important regulatory functions in EMT and MET that are often regarded as important steps in metastasis formation. 12 During the complex EMT process cancer cells lose their cell polarity and cell-cell-adhesion but gain migratory and invasive mesenchymal-cell like properties. These cells can migrate from the primary tumor to distant locations via the bloodstream. [12] [13] [14] [15] The miR-200 family members, known to be inhibitors of EMT by directly targeting the Ecadherin transcriptional repressors ZEB1 and ZEB2, have shown to be downregulated during the EMT process. 12, 13, 44 Accordantly, it was shown that an upregulation of the miR-200 family members promotes the MET process, required for the settlement and the clonal outgrow at the metastatic site 16 and thus enhances in vitro motility and in vivo metastasis. 45 This is in line with our findings of low levels of circulating miR-200b and 200c associated with a 'bad' prognosis subtype OR, odds ratio; HR, hazard ratio; CI, confidence interval. 
in non-metastatic CRC (EMT state) and in contrast increased levels of miR-141, miR-200a and miR-200b in metastatic compared to non-metastatic CRC patients, as well as the decreased survival time we found associated with elevated miR-200a levels in metastatic CRC patients (MET state). These results indicate a different role of plasma miR-200 family members in non-metastatic and metastatic CRC, in accordance with the complex changes during the EMT and MET process. In our study elevated miR-429 levels correlated to higher grading and higher miR-200a, miR-200b and miR200c levels were associated with the increasing severity of the recurrence event in metastatic CRC patients.
Higher circulating miR-200 family levels and the association with poor prognosis were described before 11, 21, 23, 46 whereas other studies in tissue or cell lines reported reduced levels of the miR-200 family members with increased disease severity. [47] [48] [49] [50] [51] However, there are also recent reports showing elevated miR-200 family expression in metastatic tissue in contrast to primary CRC. 18, 21 While it is often suggested that EMT/MET processes are pivotal for invasion and metastasis, recent reports link the observed effects predominantly towards resistance to chemotherapeutic agents. 19, 20 Thus, the association of these processes with invasion and metastasis may be highly context specific. A general issue of circulating miRNA studies is the lack of a solid and common normalization strategy for miRNA expression values. 52 Due to the heterogeneity of the origin of circulating miRNAs and their differential release into the blood stream as well as their variable expression in different tissues, development stages and disease conditions, the identification of universal endogenous controls is extremely difficult, if not impossible. Therefore the use of external controls and especially the standardization of sample collection and processing are indispensable steps in circulating miRNA studies. Although the sample size is quite large, the explorative analysis is still limited by statistical power. This can be explained by the heterogeneous characteristics of the study cohort that was not artificially idealized to facilitate the detection of new biomarkers. However, this cohort is appropriate to test the stability and reliability of formerly described markers in a realistic clinical setup.
In conclusion, the identified miRNA markers miR-122 and some miR-200 family members could be of potential use in the development of a multi-marker blood test for CRC prognosis. These miRNAs could be especially helpful for therapy monitoring of non-metastatic CRC patients to predict relapse and the occurrence of metastasis (especially liver metastasis). Adjusted treatment, depending on the prognosis, could result in an improvement of patient survival.
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